Panagora Asset Management Inc. Boosts Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT)

Panagora Asset Management Inc. increased its holdings in Sight Sciences, Inc. (NASDAQ:SGHT) by 198.1% during the 4th quarter, Holdings Channel reports. The firm owned 59,190 shares of the company’s stock after buying an additional 39,333 shares during the period. Panagora Asset Management Inc.’s holdings in Sight Sciences were worth $305,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of SGHT. Boston Partners raised its holdings in Sight Sciences by 3.1% in the 3rd quarter. Boston Partners now owns 331,776 shares of the company’s stock worth $1,117,000 after purchasing an additional 9,919 shares in the last quarter. Swiss National Bank raised its stake in Sight Sciences by 19.5% in the third quarter. Swiss National Bank now owns 69,314 shares of the company’s stock worth $234,000 after buying an additional 11,300 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Sight Sciences by 100.0% in the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $202,000 after buying an additional 30,000 shares during the period. Finally, First Eagle Investment Management LLC boosted its position in Sight Sciences by 45.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 587,297 shares of the company’s stock valued at $1,979,000 after acquiring an additional 183,912 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Stock Up 5.5 %

Shares of SGHT opened at $5.57 on Friday. Sight Sciences, Inc. has a 52 week low of $1.04 and a 52 week high of $9.73. The company has a debt-to-equity ratio of 0.31, a current ratio of 13.01 and a quick ratio of 12.42. The business’s 50 day moving average price is $5.45 and its 200-day moving average price is $4.51.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, May 2nd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. The company had revenue of $19.27 million during the quarter, compared to analysts’ expectations of $18.34 million. On average, equities analysts predict that Sight Sciences, Inc. will post -1.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday, May 3rd. Piper Sandler reissued a “neutral” rating and set a $6.00 price objective (up previously from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.70.

Insider Activity at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the transaction, the chief financial officer now directly owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Paul Badawi sold 12,571 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the transaction, the chief executive officer now directly owns 5,750,729 shares of the company’s stock, valued at $29,213,703.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the sale, the chief financial officer now owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,195 shares of company stock valued at $244,193. 28.90% of the stock is owned by insiders.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.